Privately, but he was turned down. Then, he attacked SRPT on his conference call when he compared the two data. This is something never ever happened in the history of Pharmaceuticals business. Just saying!
The European Central Bank president will announce a 550 billion-euro ($640 billion) bond-purchase program this week to make his biggest push yet to steer the euro area away from deflation by announcing quantitative easing on Jan. 22, according to 93 percent of respondents in a Bloomberg News survey. The median estimate of the size of the package tops the 500 billion euros in models presented to officials this month. This may push VJET up slightly tomorrow.
"With greater than three years of eteplirsen experience, the clinical outcomes that our team has demonstrated in the testing of these boys exhibit greater stability in function than anticipated at a time when we often observe a more significant decline without treatment. Based on my many years of caring for patients with this devastating disease, I view these more than 3 years of data as very encouraging," said Jerry Mendell, M.D., director of the Centers for Gene Therapy and Muscular Dystrophy at Nationwide Children’s Hospital and principal investigator of Study 202. "The safety profile of eteplirsen continues to impress me. We have not witnessed any clinically meaningful treatment-related adverse events during the 168 weeks of eteplirsen treatment."
Billy Ellsworth is taking a different exon-skipping drug, eteplirsen, developed by Sarepta Therapeutics. The two drugs are different chemically, and it is possible that eteplirsen may prove more effective.